Survival outcomes and practice trends for off-label use of adjuvant targeted therapy in high-risk locoregional renal cell carcinoma
- 1 June 2020
- journal article
- research article
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 38 (6) , 604.e1-604.e7
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Adjuvant Vascular Endothelial Growth Factor–targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled AnalysisEuropean Urology, 2018
- Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trialAnnals of Oncology, 2018
- Adjuvant Therapies in Nonmetastatic Renal-Cell Carcinoma: A Review of the LiteratureClinical Genitourinary Cancer, 2018
- Adjuvant Antiangiogenic Agents in Post-nephrectomy Renal Cell Carcinoma: A Systematic Review and Meta-analysisEuropean Urology Oncology, 2018
- Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell CarcinomaJournal of Clinical Oncology, 2017
- Adjuvant sunitinib for high-risk-resected renal cell carcinoma: a meta-analysis of ASSURE and S-TRAC trialsAnnals of Oncology, 2016
- Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after NephrectomyNew England Journal of Medicine, 2016
- Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trialThe Lancet, 2016
- Approval Summary: Sunitinib for the Treatment of Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors and Advanced Renal Cell CarcinomaClinical Cancer Research, 2007
- Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent diseaseUrologic Clinics of North America, 2003